Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study.

In 376 diabetic patients allocated either aspirin or placebo, there was a nonsignificant trend toward benefit for serious vascular events with a rate ratio of 0.88 (95% CI 0.67–1.15) favoring aspirin, but mortality data were not reported for this small subgroup ( 6 ).

also in 5,406 other papers